Dr. Blumenthal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8901 Wisconsin Ave
National Navy Medical Center Bldg. 8, Rm. 4152
Bethesda, MD 20889Phone+1 301-435-5868- Is this information wrong?
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
- University of MarylandResidency, Internal Medicine, 2003 - 2006
- University of Maryland School of MedicineClass of 2003
Certifications & Licensure
- MD State Medical License 2006 - 2024
- NC State Medical License 2011 - 2012
Awards, Honors, & Recognition
- Commissioner’s Special Citation FDA, 2014
- Recognition Award FDA CDER Group, 2011
Publications & Presentations
PubMed
- US FDA's Dose Optimization Postmarketing Requirements and Commitments of Oncology Approvals and the Impact on Product Labels from 2010 to 2022: An Emerging Landscape f...Gendy, J., Nomura, N., Stuart, J., Blumenthal, G.> ;Therapeutic Innovation & Regulatory Science. 2024 Mar 1
- 1 citationsThe Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibo...Qi Liu, Raina Mathur, Yuan Xu, Aracelis Z Torres, Rebecca A Miksad, Chao Liu, Haixia Smithson, Yaning Wang, Hao Zhu, Brian Booth, Shiew-Mei Huang, Jizu Zhi, Rajeshwari...> ;Clinical Pharmacology and Therapeutics. 2023 May 1
- 3 citationsClinical Trial Diversity in Oncology: FDA Takes Action with Post-Marketing Requirements or Commitments.Janice Kim, Robert Kester, Gideon Blumenthal> ;The Oncologist. 2022 Dec 9
- Join now to see all
Journal Articles
- Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in Clinical Trials of Patients with Non-Small Cell Lung CancerG R Oxnard, G M Blumenthal, P G Kluetz, R Pazdur, Annals of Oncology
- FDA Innovation Brings New Therapies to Lung Cancer PatientsPazdur R, Blumenthal G, FDA Voice Blog, 5/5/2014
- Inside the Black Box: Molecularly Targeted Therapy for Lung CancerBlumenthal G, Mansfield E, The ASCO Post, 1/15/2014
- Join now to see all
Abstracts/Posters
- Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare AnalysisGideon Blumenthal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC).Cortazar C, Zhang L, Untch M, Mehta K, Constantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Zujewski J, Justice R, Loibl S, Wickerham L, Bogaerts J,..., General Session I, San Antonio Breast Cancer Symposium, 12/5/2012
- Sunitinib for the treatment of pancreatic neuroendocrine tumor (pNET)Blumenthal G.M., Oncologic Drug Advisory Committee, Silver Spring, MD, 4/12/2011
- Join now to see all
Lectures
- Histologic-Agnostic Trials: Challenges and Opportunities—A Regulatory PerspectiveASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Analysis of Immune-Related Adverse Reactions in Patients with Classical Hodgkin Lymphoma (cHL) on Programmed Death-1 (PD-1) Inhibitor Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- When don’t we need a phase III trial?Chicago, IL - 5/1/2014
- Join now to see all
Press Mentions
- How to Succeed in Modernizing Clinical TrialsJanuary 10th, 2017
- Public Workshop - Next Generation Sequencing-Based Oncology Panels, February 25, 2016February 25th, 2016
- Special Issue Looks at What’s Ahead in Precision MedicineAugust 16th, 2015
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Holy Cross HospitalSilver Spring, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: